Aprotinin: Safe and effective in all patients undergoing orthotopic liver transplantation?

Liver Transplantation

Volumn 7, Issue 9, 2001, Pages 808-810

  Porte, Robert J ^a   Slooff, Maarten J H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; KALLIKREIN; PLACEBO; PLASMIN; SERINE PROTEINASE INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

BILIARY CIRRHOSIS; BINDING AFFINITY; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EDITORIAL; ERYTHROCYTE TRANSFUSION; FIBRINOLYSIS; HUMAN; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; THROMBOEMBOLISM;

EID: 0034855713     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2001.27085     Document Type: Article

References (32)

1. A surgeon's perspective on the management of coagulation disorders before liver transplantation
2. The impact of operative bleeding on outcome in transplantation of the liver
3. Effect of intraoperative blood transfusion on patient outcome in hepatic transplantation
4. Blood loss in orthotopic liver transplantation: A retrospective analysis of transfusion requirements and the effects of autotransfusion of cell saver blood in 164 consecutive patients
5. Coagulation and fibrinolysis in orthotopic liver transplantation: Current views and insights
6. Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation
7. Clinical application of inhibitors of fibrinolysis
8. High-dose aprotinin in cardiac surgery: Three years' experience in 1,784 patients
9. Aprotinin therapy
10. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting
11. Effect of aprotinin on intraoperative bleeding and fibrinolysis in liver transplantation
12. Aprotinin and reduction of blood loss and transfusion requirements in orthotopic liver transplantation
13. Aprotinin reduces the need for blood products during liver transplantation
14. Continuous small-dose aprotinin controls fibrinolysis during orthotopic liver transplantation
15. The prophylactic effect of aprotinin on intraoperative bleeding in liver transplantation: A randomized clinical study
16. Aprotinin and transfusion requirements in orthotopic liver transplantation: A multicentre randomised double-blind study
17. Aprotinin reduces red blood cell transfusion in orthotopic liver transplantation: A prospective, randomized, double-blind study
18. Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation
19. Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography
20. Poor prediction of blood transfusion requirements in adult liver transplantations from preoperative variables
21. Evidence for the detrimental role of proteolysis during liver preservation in humans
22. A fatal thrombotic complication during liver transplantation after aprotinin administration
23. Reduction in requirements for allogeneic blood products: Pharmacologic methods
24. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: A meta-analysis of clinically relevant endpoints
25. Aprotinin: Safe and effective only with the full-dose regimen
26. Improved haemodynamic stability with administration of aprotinin during orthotopic liver transplantation
27. Reduced need for vasopressors in patients receiving aprotinin during orthotopic liver transplantation
28. Treatment of preservation/reperfusion liver injury by the protease inhibitor aprotinin after cold ischemic storage
29. Improved early graft survival in patients receiving aprotinin during orthotopic liver transplantation
30. Aprotinin for the pretreatment of liver allograft donors
31. Prognostic factors for long-term actual patient survival after orthotopic liver transplantation in children
32. Early vascular complications after pediatric liver transplantation